User:FeyUnlocked/Viral envelope: Difference between revisions
Extra credit 2 |
m →References: task, replaced: Virusdisease → VirusDisease |
||
(2 intermediate revisions by one other user not shown) | |||
Line 38: | Line 38: | ||
# TAM receptor tyrosine kinases increase phagocytic clearance of apoptotic cells and inhibit immunological responses brought on by Toll-like receptors and type I interferons when they are activated by the ligands Gas6 and Protein S. (IFNs). The phospholipid phosphatidylserine may be seen on the membranes of several enveloped viruses, which they employ to bind Gas6 and Protein S to activate TAM receptors. Ligand-coated viruses stimulate type I IFN signaling, activate TAM receptors on dendritic cells (DCs), and suppress type II IFN signaling to circumvent host defenses and advance infection. TAM-deficient DCs exhibit type I IFN responses that are more pronounced than those of wild-type cells in response to viral exposure. As a result, flaviviruses and pseudo typed retroviruses have a harder time infecting TAM-deficient DCs, albeit infection can be brought back by type I IFN antibodies. A TAM kinase inhibitor, meanwhile, prevents infection of wild-type DCs. TAM receptors, which are potential targets for therapy, are thereby activated by viruses to reduce type I IFN signaling. |
# TAM receptor tyrosine kinases increase phagocytic clearance of apoptotic cells and inhibit immunological responses brought on by Toll-like receptors and type I interferons when they are activated by the ligands Gas6 and Protein S. (IFNs). The phospholipid phosphatidylserine may be seen on the membranes of several enveloped viruses, which they employ to bind Gas6 and Protein S to activate TAM receptors. Ligand-coated viruses stimulate type I IFN signaling, activate TAM receptors on dendritic cells (DCs), and suppress type II IFN signaling to circumvent host defenses and advance infection. TAM-deficient DCs exhibit type I IFN responses that are more pronounced than those of wild-type cells in response to viral exposure. As a result, flaviviruses and pseudo typed retroviruses have a harder time infecting TAM-deficient DCs, albeit infection can be brought back by type I IFN antibodies. A TAM kinase inhibitor, meanwhile, prevents infection of wild-type DCs. TAM receptors, which are potential targets for therapy, are thereby activated by viruses to reduce type I IFN signaling. |
||
# Numerous human pathogenic viruses in circulation are encased in lipid bilayers, and they infect their target cells by causing the viral envelope and cell membrane to fuse. Although there are effective vaccines against some of these viruses, there is no preventative or curative medicine for the majority of them. In most cases, the known vaccines operate by inducing antibodies that prevent the pathogen from entering cells. This happens in the case of enveloped viruses when the antibodies bind to the viral envelope proteins. The membrane fusion event that triggers viral entrance is caused by the viral fusion protein. Many enveloped viruses only have one protein visible on the surface of the particle, which is required for both mediating adhesion to the cell surface and for the subsequent membrane fusion process. To create potentially protective vaccines for human pathogenic enveloped viruses for which there is currently no vaccine, it is essential to comprehend how antibodies interact with viral envelope proteins, particularly with the fusion protein, and how antibodies neutralize viruses. |
# Numerous human pathogenic viruses in circulation are encased in lipid bilayers, and they infect their target cells by causing the viral envelope and cell membrane to fuse. Although there are effective vaccines against some of these viruses, there is no preventative or curative medicine for the majority of them. In most cases, the known vaccines operate by inducing antibodies that prevent the pathogen from entering cells. This happens in the case of enveloped viruses when the antibodies bind to the viral envelope proteins. The membrane fusion event that triggers viral entrance is caused by the viral fusion protein. Many enveloped viruses only have one protein visible on the surface of the particle, which is required for both mediating adhesion to the cell surface and for the subsequent membrane fusion process. To create potentially protective vaccines for human pathogenic enveloped viruses for which there is currently no vaccine, it is essential to comprehend how antibodies interact with viral envelope proteins, particularly with the fusion protein, and how antibodies neutralize viruses. Enveloped viruses enter cells by joining a cellular membrane to their lipid bilayer membrane. Priming by proteolytic processing, either of the fusion protein or of a companion protein, is necessary for the majority of viral fusion proteins. The priming stage then gets the fusion protein ready for triggering by the processes that go along with attachment and uptake, which frequently happens during transport of the fusion protein to the cell surface but may also happen extracellularly. So far, structural studies have revealed two kinds of viral fusion proteins. These proteins are believed to catalyze the same mechanism in both situations, resulting in the fusing of two bilayers. In other words, these proteins operate as enzymes, which while having various structural variations catalyze the same chemical reaction. |
||
# Viral glycoproteins, a new class of cellular inhibitory proteins has been discovered. These include the E3 ubiquitin ligases of the membrane-associated RING-CH (MARCH) family, which among other things, inhibits the expression of cell surface proteins implicated in adaptive immunity. |
|||
# One of the main parts of human pathogenic viruses is glycoprotein. They have been shown to play significant roles in immunity and infection |
|||
# Many enveloped viruses mature by budding at the plasma membrane, which allows them to be discharged from infected cells. During this procedure, viral transmembrane proteins, also known as "spike" proteins, are integrated into membrane vesicles containing viral core components. For a very long time, it was thought that the spike proteins, which are necessary for infectivity, were directly incorporated into the viral core through their cytoplasmic domains. Recent research suggests that while such direct interactions may be what causes the budding of alphaviruses, this may not be the case for retroviruses and negative strand RNA viruses. These viruses can form bud particles even in the absence of spike proteins by relying only on viral core components. The spike proteins can occasionally be produced as virus-like particles without the viral core. Therefore, optimal budding and release may be dependent on a coordinated "push-and-pull" action between core and spike, where oligomerization of both components is essential. |
|||
# The virus wraps its delicate nucleic acid with a protein shell known as the capsid, from the Latin capsa, meaning "box," in order to shield it from this hostile environment. Similar to how numerous bricks come together to form a wall, the capsid is made up of one or more distinct protein types that repeatedly repeat to form the whole capsid. This repetitive pattern creates a robust but rather flexible capsid. The nucleic acid inside the capsid is appropriately protected by its modest size and physical difficulty in opening it. The nucleocapsid of the virion is made up of the nucleic acid and the capsid. Remember that the genomes of most viruses are very small. Genes code for instructions to make proteins, so small genomes cannot code for many proteins. Therefore, the virion capsid consists of one or only a few proteins that repeat over and over to form the structure. The viral nucleic acid would be physically too large to fit inside the capsid if it consisted of more than a few proteins. |
|||
'''References''' |
'''References''' |
||
* Bhattacharyya, S., Zagórska, A., Lew, E. D., Shrestha, B., Rothlin, C. V., Naughton, J., Diamond, M. S., Lemke, G., & Young, J. A. T. (2013, August 14). ''Enveloped viruses disable innate immune responses in dendritic cells by direct activation of Tam Receptors''. Cell host & microbe. Retrieved December 1, 2022, from <nowiki>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779433/</nowiki> |
* Bhattacharyya, S., Zagórska, A., Lew, E. D., Shrestha, B., Rothlin, C. V., Naughton, J., Diamond, M. S., Lemke, G., & Young, J. A. T. (2013, August 14). ''Enveloped viruses disable innate immune responses in dendritic cells by direct activation of Tam Receptors''. Cell host & microbe. Retrieved December 1, 2022, from <nowiki>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779433/</nowiki> |
||
* Author links open overlay panelFelix A.Rey1PersonEnvelopeShee-MeiLok2PersonEnvelope, A.Rey1PersonEnvelope, F., 1, Shee-MeiLok2PersonEnvelope, 2, & Enveloped viruses enter cells by inducing fusion of viral and cellular membranes. (2018, March 8). ''Common features of enveloped viruses and implications for immunogen design for next-generation vaccines''. Cell. Retrieved December 1, 2022, from <nowiki>https://www.sciencedirect.com/science/article/pii/S0092867418302319?via%3Dihub</nowiki> |
* Felix A. Ray Author links open overlay panelFelix A.Rey1PersonEnvelopeShee-MeiLok2PersonEnvelope, A.Rey1PersonEnvelope, F., 1, Shee-MeiLok2PersonEnvelope, 2, & Enveloped viruses enter cells by inducing fusion of viral and cellular membranes. (2018, March 8). ''Common features of enveloped viruses and implications for immunogen design for next-generation vaccines''. Cell. Retrieved December 1, 2022, from <nowiki>https://www.sciencedirect.com/science/article/pii/S0092867418302319?via%3Dihub</nowiki> |
||
* Lun CM;Waheed AA;Majadly A;Powell N;Freed EO; (n.d.). ''Mechanism of viral glycoprotein targeting by membrane-associated ring-ch proteins''. mBio. Retrieved December 3, 2022, from <nowiki>https://pubmed.ncbi.nlm.nih.gov/33727347/</nowiki> |
|||
* S;, B. N. M. (n.d.). ''Viral glycoproteins: Biological role and application in diagnosis''. VirusDisease. Retrieved December 3, 2022, from <nowiki>https://pubmed.ncbi.nlm.nih.gov/26925438/</nowiki> |
|||
* https://pubmed.ncbi.nlm.nih.gov/9394621/ |
|||
* https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150055/ |
|||
[[Category:Wikipedia Student Program]] |
[[Category:Wikipedia Student Program]] |
Latest revision as of 18:47, 29 November 2024
Article Draft (FeyUnlocked)
[edit]Being made up mostly of host membrane, the viral envelope can also have the proteins associated with the host cell within their membrane after budding. (Gelderblom)
These glycoproteins mediate the interaction between virion and host cell, typically initiating the fusion between the viral envelope and the host's cellular membrane. (Navaratnarajah)
In some cases, the virus with an envelope will form an endosome within the host cell. (White)
Vaccination against enveloped viruses can function by neutralizing the glycoprotein activity with antibodies. (Rey)
References
[edit]Gelderblom HR. Structure and Classification of Viruses. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 41. Available from: https://www.ncbi.nlm.nih.gov/books/NBK8174/
Navaratnarajah, C.K. et al. “Assembly of Viruses: Enveloped Particles.” Encyclopedia of Virology (2008): 193–200. doi:10.1016/B978-012374410-4.00667-1
White, Judith M, and Gary R Whittaker. “Fusion of Enveloped Viruses in Endosomes.” Traffic (Copenhagen, Denmark) vol. 17,6 (2016): 593-614. doi:10.1111/tra.12389
Rey, F. A., & Lok, S.-M. (2018, March 8). Common features of enveloped viruses and implications for immunogen design for next-generation vaccines. Cell. Retrieved October 18, 2022, from https://www.sciencedirect.com/science/article/pii/S0092867418302319#:~:text=The%20known%20vaccines%20typically%20work,reaction%20that%20allows%20viral%20entry.
Everything in the above section was moved into the main article.
Article Draft (Boom4life) --This has been moved over to the main article--
[edit]- The capsid, having a focused role of protecting the genome in addition to immune recognition evasion (Stuart 2019).
- Viral envelope persistence, wither it be enveloped or naked, are a factor in determining longevity of a virus on inanimate surfaces (Firquet 2015)
- The particular set of viral proteins are engaged in a series of structural changes. When these changes are set/finished, there is then and only then, fusion with the host membrane (Benhaim 2020).
- The viral capsid is known for its protection of RNA before it is inserted into the host cell, unlike the viral envelope which protects the protein capsid (Cliver 2009).
"The cell from which a virus buds often dies or is weakened, and sheds more viral particles for an extended period. The lipid bilayer envelope of these viruses is relatively sensitive to desiccation, heat, and amphiphiles such as soap and detergents, therefore these viruses are easier to sterilize than non-enveloped viruses, have limited survival outside host environments, and typically must transfer directly from host to host."
References
[edit]- Firquet S, Beaujard S, Lobert P-E, Sané F, Caloone D, Izard D, Hober D. 2015. Survival of Enveloped and Non-Enveloped Viruses on Inanimate Surfaces. Microbes and Environments. 30(2):140–144. doi:10.1264/jsme2.me14145. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462923/.
- Stuart DI, Ren J, Wang X, Rao Z, Fry EE. Hepatitis A Virus Capsid Structure. Cold Spring Harb Perspect Med. 2019 May 1;9(5):a031807. doi: 10.1101/cshperspect.a031807. PMID: 30037986; PMCID: PMC6496327. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496327/
- Benhaim MA, Lee KK. 2020. New Biophysical Approaches Reveal the Dynamics and Mechanics of Type I Viral Fusion Machinery and Their Interplay with Membranes. Viruses. 12(4):E413. doi:10.3390/v12040413. [accessed 2022 Oct 28]. https://pubmed.ncbi.nlm.nih.gov/32276357/.
- Cliver DO. 2009. Capsid and Infectivity in Virus Detection. Food and Environmental Virology. 1(3-4):123–128. doi:10.1007/s12560-009-9020-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837222/#:~:text=The%20essential%20functions%
Extra credit (Boom4life)
- TAM receptor tyrosine kinases increase phagocytic clearance of apoptotic cells and inhibit immunological responses brought on by Toll-like receptors and type I interferons when they are activated by the ligands Gas6 and Protein S. (IFNs). The phospholipid phosphatidylserine may be seen on the membranes of several enveloped viruses, which they employ to bind Gas6 and Protein S to activate TAM receptors. Ligand-coated viruses stimulate type I IFN signaling, activate TAM receptors on dendritic cells (DCs), and suppress type II IFN signaling to circumvent host defenses and advance infection. TAM-deficient DCs exhibit type I IFN responses that are more pronounced than those of wild-type cells in response to viral exposure. As a result, flaviviruses and pseudo typed retroviruses have a harder time infecting TAM-deficient DCs, albeit infection can be brought back by type I IFN antibodies. A TAM kinase inhibitor, meanwhile, prevents infection of wild-type DCs. TAM receptors, which are potential targets for therapy, are thereby activated by viruses to reduce type I IFN signaling.
- Numerous human pathogenic viruses in circulation are encased in lipid bilayers, and they infect their target cells by causing the viral envelope and cell membrane to fuse. Although there are effective vaccines against some of these viruses, there is no preventative or curative medicine for the majority of them. In most cases, the known vaccines operate by inducing antibodies that prevent the pathogen from entering cells. This happens in the case of enveloped viruses when the antibodies bind to the viral envelope proteins. The membrane fusion event that triggers viral entrance is caused by the viral fusion protein. Many enveloped viruses only have one protein visible on the surface of the particle, which is required for both mediating adhesion to the cell surface and for the subsequent membrane fusion process. To create potentially protective vaccines for human pathogenic enveloped viruses for which there is currently no vaccine, it is essential to comprehend how antibodies interact with viral envelope proteins, particularly with the fusion protein, and how antibodies neutralize viruses. Enveloped viruses enter cells by joining a cellular membrane to their lipid bilayer membrane. Priming by proteolytic processing, either of the fusion protein or of a companion protein, is necessary for the majority of viral fusion proteins. The priming stage then gets the fusion protein ready for triggering by the processes that go along with attachment and uptake, which frequently happens during transport of the fusion protein to the cell surface but may also happen extracellularly. So far, structural studies have revealed two kinds of viral fusion proteins. These proteins are believed to catalyze the same mechanism in both situations, resulting in the fusing of two bilayers. In other words, these proteins operate as enzymes, which while having various structural variations catalyze the same chemical reaction.
- Viral glycoproteins, a new class of cellular inhibitory proteins has been discovered. These include the E3 ubiquitin ligases of the membrane-associated RING-CH (MARCH) family, which among other things, inhibits the expression of cell surface proteins implicated in adaptive immunity.
- One of the main parts of human pathogenic viruses is glycoprotein. They have been shown to play significant roles in immunity and infection
- Many enveloped viruses mature by budding at the plasma membrane, which allows them to be discharged from infected cells. During this procedure, viral transmembrane proteins, also known as "spike" proteins, are integrated into membrane vesicles containing viral core components. For a very long time, it was thought that the spike proteins, which are necessary for infectivity, were directly incorporated into the viral core through their cytoplasmic domains. Recent research suggests that while such direct interactions may be what causes the budding of alphaviruses, this may not be the case for retroviruses and negative strand RNA viruses. These viruses can form bud particles even in the absence of spike proteins by relying only on viral core components. The spike proteins can occasionally be produced as virus-like particles without the viral core. Therefore, optimal budding and release may be dependent on a coordinated "push-and-pull" action between core and spike, where oligomerization of both components is essential.
- The virus wraps its delicate nucleic acid with a protein shell known as the capsid, from the Latin capsa, meaning "box," in order to shield it from this hostile environment. Similar to how numerous bricks come together to form a wall, the capsid is made up of one or more distinct protein types that repeatedly repeat to form the whole capsid. This repetitive pattern creates a robust but rather flexible capsid. The nucleic acid inside the capsid is appropriately protected by its modest size and physical difficulty in opening it. The nucleocapsid of the virion is made up of the nucleic acid and the capsid. Remember that the genomes of most viruses are very small. Genes code for instructions to make proteins, so small genomes cannot code for many proteins. Therefore, the virion capsid consists of one or only a few proteins that repeat over and over to form the structure. The viral nucleic acid would be physically too large to fit inside the capsid if it consisted of more than a few proteins.
References
- Bhattacharyya, S., Zagórska, A., Lew, E. D., Shrestha, B., Rothlin, C. V., Naughton, J., Diamond, M. S., Lemke, G., & Young, J. A. T. (2013, August 14). Enveloped viruses disable innate immune responses in dendritic cells by direct activation of Tam Receptors. Cell host & microbe. Retrieved December 1, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779433/
- Felix A. Ray Author links open overlay panelFelix A.Rey1PersonEnvelopeShee-MeiLok2PersonEnvelope, A.Rey1PersonEnvelope, F., 1, Shee-MeiLok2PersonEnvelope, 2, & Enveloped viruses enter cells by inducing fusion of viral and cellular membranes. (2018, March 8). Common features of enveloped viruses and implications for immunogen design for next-generation vaccines. Cell. Retrieved December 1, 2022, from https://www.sciencedirect.com/science/article/pii/S0092867418302319?via%3Dihub
- Lun CM;Waheed AA;Majadly A;Powell N;Freed EO; (n.d.). Mechanism of viral glycoprotein targeting by membrane-associated ring-ch proteins. mBio. Retrieved December 3, 2022, from https://pubmed.ncbi.nlm.nih.gov/33727347/
- S;, B. N. M. (n.d.). Viral glycoproteins: Biological role and application in diagnosis. VirusDisease. Retrieved December 3, 2022, from https://pubmed.ncbi.nlm.nih.gov/26925438/
- https://pubmed.ncbi.nlm.nih.gov/9394621/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150055/